Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers

Pathology Research and Practice

Volumn 207, Issue 9, 2011, Pages

  Stawerski, Pawe ^a   Wgrowska Danilewicz, M ^a   Stasikowska Kanicka, Olga ^a   Danilewicz, Marian ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Ki 67; Ovarian serous tumors; Proliferation; YKL 40

Indexed keywords

GLYCOPROTEIN; KI 67 ANTIGEN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; POLAND; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 80053958249     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.06.008     Document Type: Article

References (26)

1. Bergmann O.J., Johansen J.S., Klausen T.W., Mylin A.K., Kristensen J.S., Kjeldsen E., Johnsen H.E. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin. Cancer Res. 2005, 11:8644-8652.
2. Boot R.G., van Achterberg T.A., van Aken B.E., Renkema G.H., Jacobs M.J., Aerts J.M., de Vries C.J. Strong induction of members of the chitinase family of proteins in atherosclerosis, chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 1999, 19:687-694.
3. Chetrit A., Hirsh-Yechezkel G., Ben-David Y., Lubin F., Friedman E., Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer. The National Israeli Study of Ovarian Cancer. J. Clin. Oncol. 2008, 26:20-25.
4. Chudecka-G;az A., Górski B., Zielińska D., B;ogowski W., Wojciechowska I., Bedner R., Rzepka-Górska I. Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation-comparison to CA 125 antigen. Eur. J. Gynaecol. Oncol. 2009, 30:668-671.
5. Cintin C., Johansen J.S., Christensen I.J., Price P.A., Sørensen S., Nielsen H.J. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002, 95:267-274.
6. Colombo N., Van Gorp T., Parma G., Amant F., Gatta G., Sessa C., Vergote I. Ovarian cancer. ICrit. Rev. Oncol. Hematol. 2006, 60:159-179.
7. Dehn H., Hogdall E.V., Johansen J.S., Jørgensen M., Price P.A., Engelholm S.A., Høgdall C.K. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet. Gynecol. Scand. 2003, 82:287-293.
8. Dupont J., Tanwar M.K., Thaler H.T., Fleisher M., Kauff N., Hensley M.L., Sabbatini P., Anderson S., Aghajanian C., Holland E.C., Spriggs D.R. Early detection and prognosis of ovarian cancer using serum YKL-40. J. Clin. Oncol. 2004, 22:3330-3339.
9. Hogdall E.V., Ringsholt M., Hogdall C.K., Christensen I.J., Johansen J.S., Kjaer S.K., Blaakaer J., Ostenfeld-Møller L., Price P.A., Christensen L.H. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009, 9:8.
10. Jensen B.V., Johansen J.S., Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 2003, 9:4423-4434.
11. Johansen J.S., Christensen I.J., Riisbro R., Greenall M., Han C., Price P.A., Smith K., Brünner N., Harris A.L. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res. Treat. 2003, 80:15-21.
12. Johansen J.S., Cintin C., Jørgensen M., Kamby C., Price P.A. Serum YKL-40, a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur. J. Cancer 1995, 31:1437-1442.
13. Johansen J.S., Hoyer P.E., Larsen L.A., Price P.A., Mollgard K. YKL-40 protein expression in the early developing human musculoskeletal system. J. Histochem. Cytochem. 2007, 55:1213-1228.
14. Johansen J.S., Jensen H.S., Price P.A. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. 1993, 32:949-955.
15. Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol. Biomarkers Prev. 2006, 15:194-202.
16. Johansen J.S., Williamson M.K., Rice J.S., Price P.A. Identification of proteins secreted by human osteoblastic cells in culture. J. Bone Miner. Res. 1992, 7:501-512.
17. Junker N., Johansen J.S., Andersen C.B., Kristjansen P.E. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005, 48:223-231.
18. Ł;ata E., Gisterek I., Matkowski R., Szelachowska J., Kornafel J. Znaczenie rokownicze oznaczania markera YKL-40 w surowicy i tkankach. Pol. Merkuriusz Lek. 2010, 168:505.
19. Rehli M., Krause S.W., Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997, 43:221-225.
20. Renkema G.H., Boot R.G., Muijsers A.O., Donker-Koopman W.E., Aerts J.M. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J. Biol. Chem. 1995, 270:2198-2202.
21. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000, 3:311-322.
22. Stokes D.G., Liu G., Coimbra I.B., Piera-Velazquez S., Crowl R.M., Jimenez S.A. Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum. 2002, 46:404-419.
23. Tavassoéli F.A., Devilee P. Pathology and Genetics Tumours of the Breast and Female Genital Organs 2003, IARC Press, Lyon, pp. 114-115.
24. Yang G.F., Cai P.Y., Li X.M., Deng H.X., He W.P., Xie D. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Chin. J. Cancer 2009, 28:142-145.
25. Vind I., Johansen J.S., Price P.A., Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2003, 38:599-605.
26. Zou L., He X., Zhang J.W. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz. J. Med. Biol. Res. 2010, 43(December):1232-1238.